Exact Mass: 1002.430248
Exact Mass Matches: 1002.430248
Found 28 metabolites which its exact mass value is equals to given mass value 1002.430248,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PIP(16:1(9Z)/6 keto-PGF1alpha)
C45H80O20P2 (1002.4717940000002)
PIP(16:1(9Z)/6 keto-PGF1alpha) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(16:1(9Z)/6 keto-PGF1alpha), in particular, consists of one chain of 9Z-hexadecenoyl at the C-1 position and one chain of 6-Keto-prostaglandin F1alpha at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
PIP(6 keto-PGF1alpha/16:1(9Z))
C45H80O20P2 (1002.4717940000002)
PIP(6 keto-PGF1alpha/16:1(9Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(6 keto-PGF1alpha/16:1(9Z)), in particular, consists of one chain of 6-Keto-prostaglandin F1alpha at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
PIP(16:1(9Z)/TXB2)
C45H80O20P2 (1002.4717940000002)
PIP(16:1(9Z)/TXB2) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(16:1(9Z)/TXB2), in particular, consists of one chain of 9Z-hexadecenoyl at the C-1 position and one chain of Thromboxane B2 at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
PIP(TXB2/16:1(9Z))
C45H80O20P2 (1002.4717940000002)
PIP(TXB2/16:1(9Z)) is an oxidized phosphatidylinositol phosphate (PIP). As other PIPs, oxidized phosphatidylinositol phosphates are acidic (anionic) phospholipids that consist of a phosphatidic acid backbone, linked via the phosphate group to a phosphorylated inositol (hexahydroxycyclohexane). Phosphatidylinositol phosphates are generated from phosphatidylinositols, which are phosphorylated by a number of different kinases that place the phosphate moiety on positions 4 and 5 of the inositol ring, although position 3 can also be phosphorylated. Phosphatidylinositol phosphates can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. PIP(TXB2/16:1(9Z)), in particular, consists of one chain of Thromboxane B2 at the C-1 position and one chain of 9Z-hexadecenoyl at the C-2 position. The most important phosphatidylinositol phosphate in both quantitative and biological terms is phosphatidylinositol 4-phosphate. Phosphatidylinositol and the phosphatidylinositol phosphates are the main source of diacylglycerols that serve as signaling molecules, via the action of phospholipase C enzymes. Phosphatidylinositol phosphates are usually present at low levels only in tissues, typically at about 1 to 3\\% of the concentration of phosphatidylinositol.
(2E)-6-[(2S,3R,4R,5S,6R)-5-[(2E)-6-[(2S,3R,4S,5S,6R)-6-[[(2E)-2,6-dimethyl-6-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyocta-2,7-dienoyl]oxymethyl]-3,4,5-trihydroxyoxan-2-yl]oxy-2,6-dimethylocta-2,7-dienoyl]oxy-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,6-dimethylocta-2,7-dienoic acid
phytolaccagenic acid 3-O-[alpha-L-arabinoranosyl-(1->3)-beta-D-glucuronopyranosyl]-28-O-beta-D-glucopyranoside
C48H74O22_(2E)-6-({4-O-[(2E)-6-({6-O-[(2E)-6-(beta-D-Glucopyranosyloxy)-2,6-dimethyl-2,7-octadienoyl]-beta-D-glucopyranosyl}oxy)-2,6-dimethyl-2,7-octadienoyl]-beta-D-glucopyranosyl}oxy)-2,6-dimethyl-2,7-octadienoic acid
Sacubitril/Valsartan
C48H55N6Na3O8.2.5H2O (1002.430248)
Sacubitril/Valsartan (LCZ696), comprised Valsartan and Sacubitril (AHU377) in 1:1 molar ratio, is a first-in-class, orally bioavailable, and dual-acting angiotensin receptor-neprilysin (ARN) inhibitor for hypertension and heart failure[1][2][3]. Sacubitril/Valsartan ameliorates diabetic cardiomyopathy by inhibiting inflammation, oxidative stress and apoptosis[4].
2-methyl 4a-(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2r,4ar,6as,6br,9r,10r,11s,12as,12br,14br)-10-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-13-oxo-3,4,5,6,7,8,8a,10,11,12,12b,14b-dodecahydro-1h-picene-2,4a-dicarboxylate
14'-({3-[(4-{[3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxy-6-methyloxan-2-yl)oxy]-5-hydroxy-4-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxan-2-yl}oxy)-3,4,16'-trihydroxy-5,7',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-3'-one
C47H70O23 (1002.4307670000001)
methyl 24-{[5-({5-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-4,6-dimethyl-4-nitrooxan-2-yl}oxy)-4-hydroxy-6-methyloxan-2-yl]oxy}-23-(dimethylamino)-4,8,12,22-tetrahydroxy-1,12-dimethyl-6,17-dioxo-20,25-dioxahexacyclo[19.3.1.0²,¹⁹.0⁵,¹⁸.0⁷,¹⁶.0⁹,¹⁴]pentacosa-2,4,7(16),8,14,18-hexaene-13-carboxylate
C48H62N2O21 (1002.3844882000001)
2-methyl 4a-[4,5,6-trihydroxy-3-(hydroxymethyl)oxan-2-yl] 10-[(3,4-dihydroxy-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-13-oxo-3,4,5,6,7,8,8a,10,11,12,12b,14b-dodecahydro-1h-picene-2,4a-dicarboxylate
methyl 24-{[(2s,4s,5s,6s)-5-{[(2r,4r,5r,6s)-5-{[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4,6-dimethyl-4-nitrooxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-23-(dimethylamino)-4,8,12,22-tetrahydroxy-1,12-dimethyl-6,17-dioxo-20,25-dioxahexacyclo[19.3.1.0²,¹⁹.0⁵,¹⁸.0⁷,¹⁶.0⁹,¹⁴]pentacosa-2,4,7(16),8,14,18-hexaene-13-carboxylate
C48H62N2O21 (1002.3844882000001)
2-methyl 4a-(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl (2s,4ar,6as,6br,8ar,9r,10r,11s,12as,12br,14bs)-10-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-13-oxo-3,4,5,6,7,8,8a,10,11,12,12b,14b-dodecahydro-1h-picene-2,4a-dicarboxylate
(1's,2s,3r,4r,4'r,5r,7'r,8'r,12'r,13's,14's,16'r)-14'-{[(2r,3s,4s,5r)-3-{[(2r,3s,4s,5s,6s)-4-{[(2s,3s,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-5-hydroxy-4-{[(2r,3r,4s,5s)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-3,4,16'-trihydroxy-5,7',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-3'-one
C47H70O23 (1002.4307670000001)
2-methyl 4a-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] 10-[(3,4-dihydroxy-5-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl)oxy]-11-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-13-oxo-3,4,5,6,7,8,8a,10,11,12,12b,14b-dodecahydro-1h-picene-2,4a-dicarboxylate
2-methyl 4a-(2r,3r,4r,5s,6s)-4,5,6-trihydroxy-3-(hydroxymethyl)oxan-2-yl (2s,4ar,6as,6br,8as,9r,10r,11s,12as,12bs,14bs)-10-{[(2s,3r,4r,5r)-3,4-dihydroxy-5-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-11-hydroxy-9-(hydroxymethyl)-2,6a,6b,9,12a-pentamethyl-13-oxo-3,4,5,6,7,8,8a,10,11,12,12b,14b-dodecahydro-1h-picene-2,4a-dicarboxylate
methyl (1r,12s,13r,21r,22s,23s,24s)-24-{[(2s,4s,5s,6s)-5-{[(2r,4r,5r,6s)-5-{[(2s,4s,5s,6s)-4,5-dihydroxy-6-methyloxan-2-yl]oxy}-4,6-dimethyl-4-nitrooxan-2-yl]oxy}-4-hydroxy-6-methyloxan-2-yl]oxy}-23-(dimethylamino)-4,8,12,22-tetrahydroxy-1,12-dimethyl-6,17-dioxo-20,25-dioxahexacyclo[19.3.1.0²,¹⁹.0⁵,¹⁸.0⁷,¹⁶.0⁹,¹⁴]pentacosa-2,4,7(16),8,14,18-hexaene-13-carboxylate
C48H62N2O21 (1002.3844882000001)
(1s,3as,3bs,7r,9ar,9bs,11s,11ar)-1-[(1r)-1-[(2s)-4,5-dimethyl-6-oxo-2,3-dihydropyran-2-yl]-1-hydroxyethyl]-11-hydroxy-7-{[(2r,4r,5r,6s)-3-hydroxy-6-(hydroxymethyl)-4-{[(2s,3s,4s,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-{[(2s,4s,5s,6s)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-9-yl acetate
(1'r,2s,3s,4r,4'r,5s,7's,8'r,12's,13'r,14'r,16'r)-14'-{[(2s,3r,4s,5s)-3-{[(2s,3r,4r,5s,6s)-4-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-5-hydroxy-4-{[(2s,3r,4s,5r)-3,4,5-trihydroxyoxan-2-yl]oxy}oxan-2-yl]oxy}-3,4,16'-trihydroxy-5,7',13'-trimethyl-5'-oxaspiro[oxane-2,6'-pentacyclo[10.8.0.0²,⁹.0⁴,⁸.0¹³,¹⁸]icosane]-2'(9'),18'-dien-3'-one
C47H70O23 (1002.4307670000001)